{"schema_version":"1.0","type":"article","title":"Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine","url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform-en.md","lang":"en","date":"2026-07-20","publish_at":"2026-07-20T08:58:00+08:00","updated_at":"2026-07-20","category":"商業分析系列","topic":"商業分析系列","tags":["Business Analysis","MASH","Madrigal Pharmaceuticals","Rezdiffra","resmetirom","siRNA","Ribo Life Science","Ribocure","Arrowhead Pharmaceuticals","ARO-PNPLA3","PNPLA3","THR-beta","FGF21","GLP-1","BD licensing","Taiwan biotech"],"summary":"Rezdiffra has opened the MASH market and built its commercialization infrastructure. Madrigal is now adding six Ribo siRNA programs and Arrowhead's ARO-PNPLA3 to create a cornerstone-plus-precision-combination treatment matrix.","key_points":[],"facts":[],"sections":["01 | Rezdiffra Is Highly Successful, but It Is Not the End Point for MASH","02 | Why Is Madrigal Betting on siRNA?","03 | Ribo Life Science and Ribocure: Why Did Madrigal License Six siRNA Programs at Once?","04 | Madrigal Did Not Stop with Ribo: Arrowhead Confirms siRNA as a Second Growth Engine","05 | Madrigal's Most Important Asset May Be Its MASH Commercial Infrastructure","06 | Several Taiwan MASH and Liver-Disease Programs Still Merit Attention","Conclusion | MASH Is Not a Single-Drug War; It Is a Battle of Cornerstone Therapies and Combination Matrices","References"],"references":[{"title":"[Facebook","source":"Original Drugnews post, July 20, 2026]","date":"","url":"https://www.facebook.com/61568446257142/posts/1371920785993874/"},{"title":"[FDA","source":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease, March 14, 2024]","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease"},{"title":"[New England Journal of Medicine","source":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis, 2024]","date":"","url":"https://www.nejm.org/doi/10.1056/NEJMoa2309000"},{"title":"[Madrigal","source":"2025 Full-Year Financial Results, February 19, 2026]","date":"","url":"https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0"},{"title":"[Madrigal","source":"2026 First-Quarter Financial Results, May 6, 2026]","date":"","url":"https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-first-quarter-2026-financial"},{"title":"[Novo Nordisk","source":"Wegovy Receives FDA Accelerated Approval for MASH, August 15, 2025]","date":"","url":"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916416"},{"title":"[Roche","source":"Agreement to Acquire 89bio and Pegozafermin, September 18, 2025]","date":"","url":"https://www.roche.com/media/releases/med-cor-2025-09-18"},{"title":"[Madrigal","source":"Exclusive Global License for Six Ribo siRNA Programs, February 11, 2026]","date":"","url":"https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-licensing"},{"title":"[Ribocure","source":"Ribo and Madrigal Reach First Major MASH siRNA Milestone, July 2, 2026]","date":"","url":"https://ribocure.com/news/"},{"title":"[Madrigal","source":"Global License for Arrowhead ARO-PNPLA3, May 5, 2026]","date":"","url":"https://ir.madrigalpharma.com/node/17406"},{"title":"[TaiwanJ Pharmaceuticals","source":"Company History and Liver-Disease Pipeline]","date":"","url":"https://www.taiwanj.com/pages/page_history_en"},{"title":"[Sinew Pharma","source":"SNP-630 MASH Program]","date":"","url":"https://www.sinewpharma.com/en/products-detail2-4.htm"}],"images":[{"alt":"Rezdiffra is evolving from FDA accelerated approval into a MASH cornerstone while confirmatory studies continue","url":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/figure-01.webp"},{"alt":"The MASH treatment matrix combines four complementary mechanisms: Rezdiffra, GLP-1, FGF21 and siRNA","url":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/figure-02.webp"},{"alt":"Madrigal is pursuing a dual-track siRNA strategy through Ribo's six early-stage programs and Arrowhead's clinical-stage ARO-PNPLA3","url":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/figure-03.webp"},{"alt":"Rezdiffra's clinical, diagnostic, payer and prescribing networks can amplify the commercialization of future MASH combination programs","url":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/figure-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-20）。Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine。https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-20-madrigal-mash-sirna-platform.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}